Clonidine is used for sedation in the paediatric intensive care unit. Extracorporeal membrane oxygenation (ECMO) provides temporary support if respiratory and cardiac function is threatened. ECMO influences the pharmacokinetics of drugs. Clonidine during paediatric ECMO cannot be effectively titrated as PK data are lacking. The aim of this study is to describe clonidine PK in a particular ECMO system and propose dosing guidelines for children on this particular ECMO circuit.
Introduction
Extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique providing temporary respiratory and cardiac support when survival is compromised. To date, it has been mostly used to support children, and in particular neonates [1] . The ECMO system pumps blood from a central venous site, which then flows through an oxygenator and is redirected to the patient. Two main types are distinguished. The venovenous type (VV-ECMO) ensures only lung function; the blood is returned to the right atrium. The venoarterial type (VA-ECMO) temporarily replaces both heart and lung function; the blood is ejected into the aorta to ensure organ perfusion. Furthermore, continuous venovenous hemofiltration (CVVH) can be added to the ECMO circuit to optimize fluid balance and support renal function [2] .
Patients on ECMO require optimal analgesia and sedation but effective dosing is hard to establish because the pharmacokinetics (PK) of commonly used medications is altered by the ECMO system [3] . One of these medications is clonidine, a central α-2-agonist with both sedative and analgesic properties [4, 5] . Enthusiasm for this agent is driven by concerns about the neurotoxic effects of most other sedatives noted in animal studies [6] and by the absence of clinically significant respiratory depression with central α-2 agonists [7] .
PK data are needed to rationalize drug dosing during ECMO [8, 9] but these have not yet been established for clonidine. Population PK studies delineate the influence of various determinants on drug blood level (e.g. age, organ failure, inflammation, comedication) and provide dosing guidelines adapted to a patient's individual characteristics. The aim of this study is to describe clonidine PK in a particular neonatal and paediatric ECMO and CVVH system and propose dosing guidelines for children on this particular ECMO circuit.
Methods

Setting
The Erasmus MC-Sophia Pediatric Intensive Care Unit (PICU) is a level 3 ICU and provides ECMO support to on an average 30 patients per year. This PK study included neonates and children aged up to 18 years treated with VV-ECMO and VA-ECMO between May 2007 and July 2009. It was approved by the Erasmus MC ethics review board considering that ECMO and administration of clonidine and other drugs are standard clinical care. Parental informed consent was obtained for blood sampling and PK analysis.
ECMO standard of care
The criteria for ECMO were: gestational age > 34 weeks, weight > 2 kg, mechanical ventilation <7 days and an oxygenation index >25. A clonidine infusion (0.1-1 μg kg
was added when continuous morphine (maximum 20 μg kg -1 h -1 ) and midazolam (maximum 0.3 mg kg -1 h -1 )
failed to achieve adequate sedation and then incremented stepwise to reach adequate sedation measured by the COMFORT-B scale, a validated pain and sedation scale for critically ill PICU patients [10] . Midazolam and morphine doses were adjusted by nurse-controlled sedation and used at the same doses as in non-ECMO patients (midazolam 0.05-0.3 mg kg -1 h -1 and morphine 5-20 μg kg -1 h -1 ). On the physician's discretion, clonidine boluses (1-2 μg kg -1 )
were given at start of the infusion or when the infusion rate was increased due to breakthrough distress. In the context of the PK study, no detailed data on hemodynamic effects of clonidine were collected, but clonidine boluses were frequently given and well tolerated. Occasionally, in patients on VV-ECMO with hemodynamic instability, boluses were given as a 10 min infusion and also well tolerated. Neuromuscular blockade was administered during procedures but was not routinely used. The ECMO circuit was composed of cannulas (Medtronic, Kerkrade, the Netherlands), polyvinyl chloride tubing (Bentley Bypass 70 tubing; Baxter, the Netherlands), a silicone rubber membrane oxygenator (Medtronic; for neonatal system: 1.5 m 2 Paediatric Extended Capacity Membrane Oxygenator; for paediatric system: 2.5 m 2 I-2500-2A silicone Surgical Membrane Oxygenator) and a heat exchanger (Medtronic Heat Exchanger Monitoring adapter and Luer-lock). The neonatal system was applied in children <10-12 kg and the paediatric system in children with higher weight. Priming volume was 350 ml in the neonatal and 900 ml in the paediatric system. Ninety per cent of the patients were pre-emptively treated with CVVH while on ECMO [2] . The haemofilter contains a high permeability membrane AN69 with a surface of 0.9 m 2 (Multiflow 100; Hospal, GAMBRO, Lyon, France) that was placed parallel to the ECMO circuit, distal to the ECMO roller pump.
Blood sampling
Blood samples for PK analysis were collected concomitantly with routine blood sampling three times daily. In addition, blood was sampled, if possible, before, at the time of ECMO cannulation, 1 and 3 h thereafter and after decannulation. Blood was sampled from the preoxygenator access point and collected in EDTA-decoagulation tubes.
Laboratory analysis
After centrifugation (5 min, 4000g), the supernatant serum was stored at -80°C until the assay was performed. Clonidine was analysed using liquid chromatography-tandem mass spectrometry in the positive ionisation mode. To precipitate proteins, 50 μl tri-chloroacetic acid containing the internal standard clonidine-d4 was added to 20 μl of plasma. Samples were vortexed, stored at -20°C for 30 min, vortexed again and centrifuged (4 min at 2750g). For the determination of clonidine 5 μl of the sample solution was injected onto a Thermo Scientific Hypersil Gold (50 × 2.1 mm, 1.9 μm) column. A chromatographic gradient was applied using an acetonitrile and water mixture with a constant 5% addition of 1% ammonium formate/2% formic acid in water. The flow was 600 μl/min. Clonidine was measured as [M + H] + , using the mass transition 232.1/44.0 and Clonidine-d4 with mass transition 236.1/48.0. The method was validated over a range of 0.100-20.0 μg/l. The accuracy ranged from 98.6% to 113.8% across the validated range, the intraday precision was below 6.4% and the interday precisions was below 6.4%.
Clinical parameters
Demographic data (weight, date of birth, sex, gestational age where applicable) were retrieved from the electronic patient data management system. The most recently measured bodyweight prior to ECMO was used for drug dosing and PK analysis. In addition, the following data were retrieved: exact dose and time of clonidine infusion and boluses, laboratory parameters, indication for ECMO, ECMO type (VV or VA) and ECMO flows and inotropic drugs, and body temperature. As CVVH was pre-emptively applied, urine output, fluid balance, use of CVVH (and corresponding flow) and use of diuretics were considered potentially influential PK parameters and were retrieved. Concomitant medications included other analgesics and sedatives (morphine, midazolam, pentobarbital), vecuronium, antibiotics, inotropes and vasoactive drugs and diuretics (furosemide, bumetanide, spironolactone).
PK model development
The PK analysis was conducted with nonlinear mixed effect modelling software (NONMEM 7.2.0; Icon Development Solutions, Ellicott City, Maryland, USA). Nonlinear mixed effects modelling allows determination of fixed (typical values for PK parameters) and random parameters (inter-and intraindividual variability and residual variability). The firstorder conditional estimation with interaction between interindividual and residual random effect was used during the entire model development. R (version 3.1.2) [11] and Pirana (version 2.7.1) [12] were used to visualize the results and evaluate the output. The log-likelihood ratio test was the main tool for the selection between two hierarchical models, using the objective function value (OFV) produced by NONMEM. The OFV is a measurement of goodness of fit of the model and is proportional to -2 log likelihood of the data. During basic model building and covariate analysis, a difference in OFV of >10.8 (corresponding to a P-value of 0.001 assuming a Chi-square distribution) was considered statistically significant when the models differed by one parameter. Goodness of fit plots and confidence interval in parameter estimates were also evaluated during basic model building and covariate analysis. The population model was built in three steps:
1 Structural model One-, two-and three-compartment models were evaluated. Between-subject variability in clearance (Cl) and volume of distribution (V) were evaluated with exponential models:
where θ pop is the population parameter for clearance and volume of distribution, respectively, and ηi the normally distributed between-subject variability with mean 0 and variance ω 2 .
The error model characterizing the residual variability (unexplained by the model) was defined by a proportional and an additive term:
where C obs,ik is the k th observed plasma concentration for the individual i, C pred,ik the predicted plasma concentration and ε prop,ik and ε add,ik are the residual random proportional and residual errors with a mean of 0 and a variance σ 2 .
To account for variability in PK parameters due to the varying sizes of individual children, the parameter values were standardized a priori to a bodyweight (WT) of 70 kg using an allometric power model using equations (4) and (5):
2 Covariate analysis
We expected that PK parameters would be influenced by:
1 Demographic and clinical condition (sex, main diagnosis leading to ECMO). 2 Maturation: Age-related maturation is a major factor influencing PK (clearance) in children [13] . This was expected to have a major impact because the study population had a broad age range. Postmenstrual, postnatal and gestational age were tested. 3 ECMO: Physicochemical interactions between clonidine and the ECMO circuit, such as increased clearance due to adsorption to the circuit and increase in volume of distribution (VD) due to the added extracorporeal circuit [3] . The effect of a circuit change during the ECMO course was also evaluated. 4 Disease progression: indications for ECMO, organ dysfunction or systemic inflammation may affect PK [14] . Laboratory values served as surrogate markers of organ function (liver function test, urea and creatinine, lactate, albumin).
The covariate analysis was performed using the formulas described in Table 1 . Multivariate analysis was carried out stepwise, including first the parameter leading to the highest decrease in OFV. All significant parameters in the univariate analysis were tested. A decrease in OFV of 10.8 (corresponding to P = 0.001) was considered significant.
Model validation
Bootstrap analysis was performed on the final model by the use of Perl speaks NONMEM [15] ; 1000 bootstrap data sets were generated by random sampling and replacement. Median parameter values, 2.5 th and 97.5 th percentiles of parameter distribution and standard error of the estimates generated, were compared to the parameters of the final model. The model was also validated using normalized prediction distribution errors (NPDEs) that simulate prediction discrepancies between the distribution predicted and the observations from the same individual. NPDEs were calculated using a commonly-used R-package [16] .
Dosing simulations
Average curves for representative patients were simulated. Interpatient variability was not simulated due to the limited number of patients. Parameters were fixed to three different age values: 3 days, 1 month and 6 years. A start of clonidine infusion 24 h after ECMO cannulation was assumed. Table 1 Covariate analysis
Equations
Covariate tested Eq 6: Cl = Cl base · θ
CATEG
Where: Cl base corresponded to the Cl in individuals with CATEG = 0 Example: When testing sex, females were assigned CATEG = 0 and males CATEG = 1. The clearance in females was equal to Cl base, and θ is the Cl ratio of males over females. -Cli is the clearance of an individual at different time after cannulation (t EC ) -delta Cl is the maximal fractional increase or decrease of the PK parameter during ECMO -T50CL is the time to half of the maximal effect -θ tEC corresponds to the Hill exponent determining the steepness of the change in clearance. Where: V is the volume of distribution at different time after cannulation (tEC)
•VECMO is the maximal volume on ECMO •VNON is the volume of distribution off ECMO •t1/2 is the half-life of the change in volume of distribution. 
Results
Twenty-two patients were included, with median age 1 month (IQR 6.4) and median weight 4 kg (IQR 3.1) at initiation of ECMO support. Demographics and treatment details are presented in Diagnostic; n (%)
• Cardiac 4 (18.2%)
• Congenital diaphragmatic hernia 3 (13.6%)
• Meconium aspiration syndrome 5 (22.7%)
• Persistent pulmonary hypertension of the newborn 1 (4.5%)
• Pulmonary 7 (31.8%)
• Sepsis 2 (9.1%)
Clonidine use
• Time of start, days since ECMO start 2.9 (4.4)
• Patients on clonidine at ECMO start 6 (27.3%)
• Patients on clonidine at ECMO stop 17 (77.3%)
Continuous sedative started after clonidine
• Pentobarbital 3 (13.6%)
• Propofol 1 (4.5%)
• Ketamine
(22.7%)
Level of sedation (total number of observations = 706)
• Oversedation (COMFORT-B < 11) 297 (42.1%)
• Optimal sedation (COMFORT-B 11-22) 398 (56.4%)
• Undersedation (COMFORT-B > 22) 11 (1.5%)
• Therapeutic hypothermia, n (%) 1 (4.5%)
Use of diuretics
• Patient exposed to any diuretic, n (%) 16 (72.7%)
• Start prior to ECMO 10 (45.4%)
• Furosemide intermittent, n (%) 14 (63.6%)
• Spironolactone, n (%) 7 (31.8%)
• Bumetanide, n (%) 2 (9.1%)
Continuous venovenous hemofiltration (CVVH)
• Patient with CVVH, n (%) 20 (90.9%)
• CVVH flow (ml min -1 ) 300 (200) ECMO Modality:
• Venoarterial, n (%) 7 (31.8%)
• Venovenous, n (%) 15 (68.2%)
Circuit change 1 (4.5%)
Laboratory values
• Creatinine (μmol l -1 ) 27 (10)
• Albumin (g l -1 ) 32 (9)
• Aspartate transaminase (IU l -1 ) 49 (143)
Values are expressed as median and interquartile range unless specified otherwise ECMO = extracorporeal membrane oxygenation Table 2 (Continued) Figure 1 Individual clonidine concentration vs. time profiles. For every patient, the individual data are connected by a solid line Table 3 ).
Uni-covariate analysis. Table 3 gives an overview of the main models tested and their performance during univariate analysis.
Demographics
Sex and diagnosis were not significant covariates.
Maturation
Among all models accounting for the effect of age on clearance, the Hill equation using postnatal age (PNA) gave the best fit to the data: OFV decreased by 158; the standard error of the estimate (SE) and goodness of fit plots were adequate. A relationship between gestational age and clearance was not detected.
ECMO
The increase in clearance and VD with time on ECMO were best described with sigmoidal maximal effect (E max ) models. Time dependent changes in clearance or volume after ECMO decannulation were not detected. Moreover, no relationship was found between the type of ECMO (VA vs VV) and volume or clearance.
Disease progression
Laboratory values were not significant covariates. The use of CVVH and CVVH flow did not significantly affect clearance. Urinary output was proportional to clonidine Multicovariate analysis. The Hill equation using PNA was the first implemented in the structural allometric model because it was the most significant (Table 4) . Adding the effect of time on ECMO using the sigmoidal E max model on clearance did not improve the OFV and time on ECMO was therefore not included in the model. Figure 2 shows the population and individual predictions vs. observed clonidine levels (goodness of fit plots) on and off ECMO of the final model. Both urine output and use of diuretics further decreased the OFV but including both variables resulted in inflated residual standard error. Only the use of diuretics was included in the final model based on a lower standard error of the estimate. It was associated with decreased clearance (Θ DIUR = 0.66). The empirical Bayesian estimates of clearances during and off ECMO and CVVH, respectively, are depicted in Figure 3 . ECMO significantly increased VD by 55%. Maximal VD was reached 72 h after initiation of ECMO (Figure 4) . Table 3 describes the parameter values and their corresponding interpatient variability. Goodness of fit plots of the final model are depicted in Figure 5 . Typical values for clearance and VD were 29.9 l h -1 70 kg -1 and 454 l 70 kg -1 .
Introduction of the covariates to the structural model increased interpatient variability of clearance from 33 to 40% and reduced that of VD from 52-44%. The residual error decreased from 28% to 20%.
Model validation. The final model was tested with a bootstrap analysis; results are given in Table 4 . 284 Table 4 Covariate analysis Clearance simulations. Figure 6 shows the body-weight normalized clearance plotted against age, as predicted by the final model and two paediatric studies in non-ECMO patients [17, 18] . The mature clearance in ECMO patients is double the clearance in patients not on ECMO.
Dosing simulations. When clonidine is started at 24 h of ECMO support, a therapeutic clonidine plasma concentration (2 ng ml -1 ) can be reached within 1 h as follows:
• In a 3-day-old patient (3 kg): with three boluses of 5 μg kg -1 (20 min intervals) and an infusion of 0.12 μg kg -1 h -1 .
• In a 1-month-old child (4 kg): with three boluses of 5 μg kg
(20 min intervals) and an infusion of 2 μg kg -1 h -1 .
• In a 12-year-old child (35 kg): with three boluses of 5 μg kg -1 h (20 min intervals) and an infusion of 1 μg kg
Discussion
This study is the first to describe the population PK of clonidine after intravenous administration to neonates and children on ECMO. The developed PK model shows that allometrically scaled clonidine clearance increases steeply with PNA, and reaches 70% of adult clearance at 10 days of PNA. Interestingly, patients in whom diuretics were used had a lower clearance, which may be explained as patients who have reduced urine output are more likely to receive diuretics to promote diuresis. The volume of distribution increases by 55% during ECMO.
A one-compartment model was superior to a twocompartment model. Clonidine PK in paediatrics has previously been described with one [18] and two-compartments models [17, 19] . In the studies by Potts et al. [17] and Larsson et al. [19] , samples were available late after a single clonidine dose (until 24 h), which might have made it easier to distinguish a second phase in the elimination [17] . The clearance of clonidine in our study is double that reported in previous studies in non-ECMO patients. For drugs previously studied on ECMO, such as gentamicin and midazolam, the reported increase in clearance was maximally 50% [20] . The use of CVVH was not shown to influence clearance but it was applied in 90% of our patients and often used with ECMO, which may have obscured its effect on clearance. The estimated clearance on ECMO was estimated at 30 l h -1 70 kg
in our study while it was around 15 l h -1 70 kg -1 in two previous paediatric studies [17, 18] (Figure 6 ). One of these two studies reported an apparent clearance value in 36 newborns (PNA: 8.8 ± 5.5 days) treated with oral clonidine for neonatal abstinence syndrome [18] . To our knowledge, the bioavailability of clonidine in neonates has not yet been reported. Values of 50% and 90% have been reported for children and adults, respectively [19, 21] . The other study [17] pooled data from five studies including 83 patients ranging from neonatal to adolescent age treated by intravenous, rectal and epidural clonidine for sedation prior or during general surgery and after heart surgery. In studies in adults not on ECMO, oral and sublingual clonidine clearance values were similar to those found in children (14 l h -1 70 kg -1 [22, 23] ).
Figure 2
Population predicted (left) and individual predicted (right) plasma concentrations vs. observed clonidine levels on (bottom) and off (top) extracorporeal membrane oxygenation
Several factors may explain the higher clearance values during ECMO. One factor is the extracorporeal technique. The blood in the ECMO circuit is in contact with a large surface of synthetic material that adsorbs drugs [24] and thereby increases clearance. Ex vivo studies of ECMO systems show that rapidity and extent of drug adsorption increases with lipophilicity [24, 25] and amount of protein bound [26] .
The adsorption of clonidine may be expected to be high: it is moderately lipophilic (log P = 1.6) [27] and slightly protein-bound (20-40%) [28] . Ex vivo studies on clonidine are lacking; still it would be useful to delineate the losses in the ECMO and CVVH circuits and compare adsorptive capacities of different type of ECMO system. Second, 90% of the patients were on continuous renal replacement therapy. Clonidine is considered poorly dialyzable and no dosing adjustment is recommended on dialysis [29, 30] . However, its extraction ratio of 0.2-0.3 [30] and its physicochemical properties (low molecular weight and slightly protein bound) suggest considerable clearance when renal replacement therapy is continuous, despite its large VD. The concentration of clonidine in the ultrafiltrate should be determined in future studies.
We found that PNA was the main determinant of bodyweight normalized clearance. This is in line with previous studies described in Figure 6 [17, 18] . Interestingly, the sigmoidal model with PNA was described earlier by Xie et al. in a neonatal population treated with oral clonidine for neonatal abstinence syndrome [18] . These models using PNA should be interpreted with caution in the first days of life because they imply absent clearance at birth and therefore do not reflect the liver metabolism and renal clearance that start long before birth. ECMO is rarely initiated on the first day of life: the youngest patients in our study were 3 days old (n = 4) and our results probably cannot be transposed to younger neonates.
Interestingly, maturation of clearance with PNA shows a different pattern in our study: it starts at a smaller baseline value and reaches adult value at an earlier age. In our ECMO-patients, 70% of adult clearance was reached at 1.5 weeks compared to 1 month [18] and 9 months [17] in previous paediatric studies. These various patterns of clearance maturation may at least be partially explained by different age distribution: the first study included only neonates [18] while the second included only a few neonates [17] . The derived PK parameters should only be used within the age range studied. The oldest patient in our study was aged 6 years and these parameters therefore cannot be applied to older children. Drug sequestration by the ECMO circuit, improved organ perfusion and oxygenation with extracorporeal support may have contributed to the rapid increment in clearance with age.
Like ECMO and clinical condition, age may affect two clearance pathways: GFR and CYP2D6 mediated drug metabolism. The expression and activity of CYP2D6 mature rapidly between birth and age 1 week and reaches 85% of adult activity at a PNA of 2 weeks [31, 32] . We found a similar pattern. However, renal function does not reach adult values until age 8-12 months [13] , which corresponds to the pattern of clearance maturation in non-ECMO patients but is not supported by our study.
High collinearity between time-dependent variables is expected: the predominant effect of age on clearance may mask influential factors such as clinical condition, ECMO or CVVH. This confounding effect is inherent to ECMO studies. PNA reliably estimates clearance but shouldn't be interpreted as the aetiology of the increase in clearance with time. The low baseline clearance may reflect the patients' critical clinical condition at ECMO start, after which [14, 33] . Moreover, the inflammatory response triggered by the disease or the start of ECMO [34] known to induce cytochrome 2D6 downregulation could contribute to the lower baseline clearance [14, 35] . The influence of ECMO and CVVH on clearance probably drives the rapid increase of clearance with age.
Although clonidine is approximately 50% renally excreted, creatinine could not be used to estimate renal function because it is also cleared by CVVH. Diuretics use was associated with a 34% lower clearance. In our PICU, CVVH is used early or pre-emptively in patients on ECMO [2] and therefore native renal clearance may also have contributed to clonidine clearance as suggested by the proportional relationship between urine output and clearance. Adequate urine output is aimed for while on CVVH. Our team has reported diuretic use as risk factor of acute kidney injury (AKI) post-ECMO in the same population [36] . The doses of loop diuretics were the only factor associated with AKI. During ECMO, diuretics are used for oliguria that may be caused by excessive CVVH fluid removal or to AKI related to the patient's medical condition. Similarly, the decreased clonidine clearance associated with diuretic use in this study can reflect both conditions.
The VD was 454 l 70 kg -1 at ECMO start and increased by 55% during ECMO. In a study using a onecompartment pharmacokinetic model the VD of oral clonidine in non-ECMO neonates was 391 l 70 kg -1 [18] . High increases of VD have also been reported for other drugs administered during ECMO [20, 37] . To illustrate this: a doubling in case of a hydrophilic drug and a 400% increase Predicted body-weight normalized clearance profile according to postnatal age in extracorporeal membrane oxygenation vs. non-extracorporeal membrane oxygenation paediatric studies. Clearance is depicted only from day 3 (age of the youngest patients [34] , induces a capillary leak and fluid retention that can change drug distribution and increase VD. While fluid retention is more likely to affect VD of hydrophilic drugs, the inflammatory response also involves the central nervous system and alters permeability of the blood-brain barrier [38] and may therefore impact VD of lipophilic drugs. Possible causes of the increase in VD of lipophilic drugs need to be further studied. The composition of the ECMO system has an impact on plasma drug level [24] and may have influenced the pharmacokinetics of clonidine. At the time of the study a circuit with a high adsorptive capacity was used. Many PICUs have switched to circuits made from polymethylpentene hollow fibre, which are associated with less adsorption. Clearance may therefore be lower with the new generation of ECMO circuits. Moreover, the priming volume was higher than in the newer ECMO systems. Furthermore, the newer ECMO systems are likely to lead to less inflammation. Each of these properties may potentially influence clonidine PK.
In many PICUs the clonidine infusion rate has increased in recent years. At the time of our study it was 0.1-1 μg kg -1 h -1 in our PICU vs. 1-3 μg kg -1 h -1 in a recent PICU trial [4, 39] . The clonidine level obtained in this study can therefore not be compared with that obtained in more recent studies. The targeted clonidine plasma concentrations in the PICU have not yet been formally determined with PK/PD studies. Studies in healthy adult volunteers [40] and limited data in critically ill children [41] suggest a level of 2 ng ml -1
to ensure sedation and analgesia. The rapid increase in clearance during the first 2 weeks of life suggests that the infusion should regularly be incremented in early life. As we found that the clonidine clearance in children older than 1 month was two-fold the adult clearance, the infusion rate may need to be doubled from 1 month of PNA to reach the same steady state concentration. Currently, the maximal recommended bolus dose is 5 μg kg -1 . We simulated the number of bolus doses of 5 μg kg -1 needed to reach the target concentration of 2 ng ml -1 within 1 h: three repeated bolus doses of 5 μg kg -1 were needed. Our study proposes dosing recommendations based on available PK/PD data, and suggests that higher doses of clonidine infusion may be needed when ECMO is coupled to CVVH. Future research should focus on hemodynamic tolerance of these higher clonidine doses particularly in children on VV ECMO. This study draws a framework to delineate clonidine PK in other populations on different extracorporeal systems.
Limitations of the study
First, the single centre nature of this study may limit its generalizability. Second, the newer generation of ECMO systems may have different influence on pharmacokinetics of clonidine. Moreover, this study involved a limited number of patients.
Conclusion
This study demonstrates that in children on the studied ECMO system combined with CVVH, the clonidine clearance is doubled and the volume of distribution is higher than reported in critically ill adults and children not on ECMO. Postnatal age is the main determinant of clearance maturation; the rapidity and extent of this maturation suggests an influence of ECMO, CVVH, CYP2D6 maturation and patient clinical condition. This study delineates a framework for studies on pharmacokinetics of clonidine on other extracorporeal systems and illustrates how dosing guidelines should be developed to account for the diversity of situations encountered in the PICU.
